The landscape for innovative pharmaceutical interventions is rapidly evolving which is translating to hope in disease areas where there is huge unmet need. To continue incentivising innovation the corresponding policy should be reviewed and updated, integrating the perspective of patients who ultimately benefit. The ‘Value of Hope’ as an important value element of new treatments and has generally been supported as a concept in literature to date, however, HTA policy assessment frameworks are less supporting and seem to be lagging in producing a standardised method to incorporate a wider perspective including Value of Hope. The aim of the symposium is to engage in a thought provoking and insightful conversation around current perceptions towards Value of Hope.

Value of Hope will be introduced as a relevant concept for HTA decision making in the era of innovative new therapies and the current landscape and gaps will be highlighted. The topic will be debated from a range of viewpoints including: a proponent of Value of Hope, an industry representative, a patient advocate and a HTA perspective. The symposium discussion, guided by the moderator, will confer ways to empirically measure hope including the practicality of those that have been researched and lesser explored methods. Novel policy concepts to integrate Value of Hope into HTA decision-making, without completely overturning current practices will be deliberated. The panellists will also discuss the relative importance of Value of Hope as a value element and consider the benefits, challenges, and controversies of incorporating it into a HTA framework.

Sponsored by Putnam Inizio Advisory